The Global Health Body Raises Alert Over Acute Scarcity of Weight-Loss Medications
Less than 10% of patients that would benefit from obesity jabs like Wegovy can access them, states the World Health Organization as it issues its initial recommendations on the drugs.
With more than one billion individuals worldwide now living with obesity, it is urging increased and just availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The latest guidance recognises that excess weight is a lifelong illness that can be treated with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are key barriers to universal availability to the jabs that can help people shift substantial weight, notes the agency.
Skinny Jab Scarcity
Even in the current most optimistic scenario, the supply of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, as stated by the health organization.
The guideline encourages governments and firms to increase availability, by strategies including patent sharing.
A patent on semaglutide – the core component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Jabs Operate
GLP-1 drugs replicate a body's own hormone to reduce digestion speed, reduce hunger and enhance the sense of being full so people reduce food intake.
Patients commonly start to lose weight in the initial weeks of commencing the once-weekly jabs.
Research indicates people may see weight return within a year of halting the drug, as their typical food cravings come back.
To be carrying excess weight increases your likelihood for experiencing health problems, like diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity concerns individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
